ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 150 mg/ml - medroxyprogesterone - medroxyprogesterone - for contraception where medically indicated and oral administration is inapplicable.

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - misoprostol - טבליה - misoprostol 200 mcg - misoprostol - misoprostol - for the treatment of duodenal and gastric ulcer.treatment and prevention nsaid induced ulcers lesions, erosions, while nsaid therapy continues.use in conjunction with mifepristone subject to the approval of a committee for the termination of pregnancy according to the israeli penal law 1977.first-trimester pregnancy failure: use is intended for emptying the uterus in states of first trimester pregnancy failure, including: presentation of a pregnancy sac in the uterus with no fetal echo, missed abortion (until week 11+6 and a fetus 40 mm in length) or incomplete abortion. the preparation is to be used after location of the sac in the uterus has been proved and the diagnosis of pregnancy failure is certain. the preparation can be used for this purpose in an ambulatory setting. the dosage and route of administration will be similar to the use of cytotec in pregnancy termination after using mifegyne. informed consent and medical surveillance are required.softening and dilation of the cervix for performing intraut

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.